Research Advances on the Relationship Between Adrenergic Signaling and Neuroblastoma and its Targeted Therapy
10.13471/j.cnki.j.sun.yat-sen.univ（med.sci）.2025.0601
- VernacularTitle:肾上腺素能与神经母细胞瘤的关系及其靶向治疗的研究进展
- Author:
Yang YANG
1
;
Xia YANG
1
Author Information
1. Department of Biochemistry and Molecular Biology， Zhongshan School of Medicine， Sun Yat-sen University， Guangzhou 510080， China
- Publication Type:Review
- Keywords:
neuroblastoma;
adrenergic;
high risk;
core regulatory circuitry;
targeted therapy
- From:
Journal of Sun Yat-sen University(Medical Sciences)
2025;46(6):907-919
- CountryChina
- Language:Chinese
-
Abstract:
Neuroblastoma （NB）， the commonest extracranial solid malignant tumor in children， is an adrenergic-derived neuroendocrine tumor characterized by highly heterogeneous clinical manifestations. Children with high-risk NB exhibit poor prognosis， often experiencing recurrence or metastasis despite intensive intervention. NB cells primarily consist of two subtypes： adrenergic （ADRN） and mesenchymal （MES）. The ADRN subtype is associated with differentiation and demonstrates greater sensitivity to differentiation-inducing agents and chemotherapeutic drugs， whereas the MES subtype correlates with invasiveness and chemotherapy resistance. Studies indicate that lineage transition between ADRN and MES subtypes contributes to tumor heterogeneity， potentially triggering chemotherapy resistance or recurrence. Elucidating the molecular mechanisms underlying their interconversion is crucial for overcoming lineage-transition-induced drug resistance and targeting ADRN in high-risk NB treatment. This article comprehensively reviews the role of adrenergic signaling in NB pathogenesis and its intrinsic molecular regulatory mechanisms while summarizing recent advances in ADRN-targeted strategies for NB clinical diagnosis and treatment， with an aim to provide a theoretical basis for future clinical management and prevention of NB.
